Artelo Biosciences Inc. (ARTLW)
NASDAQ: ARTLW
· Real-Time Price · USD
0.01
0.00 (78.57%)
At close: Jun 17, 2024, 10:00 PM
Artelo Biosciences Balance Sheet Statement
Financials in USD. Fiscal
year is
undefined.
Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 | Feb 28, 2021 |
Cash & Equivalents | 2.64M | 5.72M | 6.92M | 6.89M | 7.14M | 12.12M | 10.35M | 12.16M | 6.63M | 10.05M | 10.71M |
Short-Term Investments | 10.22M | 8.27M | 8.57M | 10.64M | 12.35M | 9.2M | 13.16M | 11.95M | 3.44M | n/a | 512.03K |
Long-Term Investments | n/a | n/a | n/a | -1.5M | -1.49M | -1.99M | n/a | 1.52M | n/a | n/a | n/a |
Other Long-Term Assets | -0.00 | 197K | 3K | 3K | 3K | 3K | 3K | 3K | 189K | n/a | n/a |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | 2M | n/a | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | -4M | n/a | n/a | n/a | n/a |
Other Current Assets | 10.79M | 611K | 903K | 789K | 2.31M | 2.95M | 3.08M | 514K | 252K | 248K | 186.74K |
Total Current Assets | 13.43M | 14.6M | 16.39M | 18.32M | 20.3M | 22.28M | 24.59M | 24.61M | 10.32M | 10.3M | 11.41M |
Property-Plant & Equipment | 29K | 39K | 50K | 60K | 70K | 81K | 73K | 81K | 90K | 63.00 | 124.00 |
Goodwill & Intangibles | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M |
Total Long-Term Assets | 2.07M | 2.27M | 2.09M | 2.1M | 2.11M | 2.12M | 2.12M | 3.64M | 2.32M | 2.04M | 2.04M |
Total Assets | 15.5M | 16.88M | 18.48M | 20.42M | 22.41M | 24.41M | 26.7M | 28.25M | 12.63M | 12.34M | 13.44M |
Account Payables | 840K | 523K | 701K | 905K | 411K | 432K | 800K | 975K | 493K | 418.94K | 583.97K |
Deferred Revenue | -32K | -523K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | 32K | 34K | 37K | 40K | 42K | 45K | 32K | 31K | 28K | n/a | n/a |
Other Current Liabilities | 49K | 569K | 87K | 53K | 27K | 50K | 43K | 21K | 5K | 5K | 5K |
Total Current Liabilities | 921K | 603K | 825K | 998K | 480K | 527K | 875K | 1.03M | 526K | 423.94K | 588.97K |
Long-Term Debt | n/a | 6K | 15K | 23K | 32K | 40K | 49K | 57K | 67K | n/a | n/a |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 418.94K | 583.97K |
Total Long-Term Liabilities | n/a | 6K | 15K | 23K | 32K | 40K | 49K | 57K | 67K | 418.94K | 583.97K |
Total Liabilities | 921K | 609K | 840K | 1.02M | 512K | 567K | 924K | 1.08M | 593K | 423.94K | 588.97K |
Total Debt | 32K | 40K | 52K | 63K | 74K | 85K | 81K | 88K | 95K | n/a | n/a |
Book Value | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Book Value Per Share | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock | 3K | 3K | 3K | 3K | 3K | 42K | 42K | 42K | 25K | 23.15K | 22.21K |
Retained Earnings | -37.24M | -34.79M | -33.19M | -31.02M | -27.68M | -25.35M | -22.9M | -20.94M | -16.9M | -15.02M | -12.77M |
Comprehensive Income | -199K | -201K | -205K | -254K | -388K | -176K | -64K | -18K | 18K | 49.38K | 47.9K |
Shareholders Equity | 14.58M | 16.27M | 17.64M | 19.4M | 21.9M | 23.84M | 25.78M | 27.17M | 12.04M | 11.92M | 12.86M |
Total Investments | 10.22M | 8.27M | 8.57M | 9.15M | 10.86M | 7.21M | 13.16M | 12.32M | 3.44M | n/a | 512.03K |